Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation

Cytomegalovirus (CMV) viremia occurs in 40% to 80% of CMV-seropositive (R+) recipients of allogeneic hematopoietic cell transplantation (HCT). The preemptive therapy (PET) strategy has reduced the risk of CMV end-organ disease (EOD) and associated mortality but may lead to substantial healthcare res...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biol Blood Marrow Transplant
Egile Nagusiak: Fang, Jiaqi, Su, Yiqi, Zavras, Phaedon D., Raval, Amit D., Tang, Yuexin, Perales, Miguel-Angel, Giralt, Sergio, Stern, Anat, Papanicolaou, Genovefa A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248281/
https://ncbi.nlm.nih.gov/pubmed/32640313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.06.025
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak